At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Apr 8, 2026 at 06:00 ET
Nurix Therapeutics (NRIX) reported Q1 2026 financial results with revenue of $6.3M, down 66% YoY, and a net loss of $87.2M ($0.79 per share), missing EPS consensus of $-0.73. The miss was driven by lower collaboration revenue as the Sanofi research term wound down, while R&D spending increased to advance bexobrutideg into pivotal trials.
- Q1 2026 revenue was $6.3M, down from $18.5M in Q1 2025, primarily due to reduced Sanofi collaboration revenue
- EPS of $-0.79 missed consensus of $-0.73 by 7.7%, reflecting higher R&D spend
- R&D expenses rose to $84.1M from $69.7M YoY due to clinical and manufacturing costs for bexobrutideg
- Cash balance was $540.7M as of February 28, 2026, with no near-term liquidity concerns
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access